Given that elevated levels of YKL-40, sTREM2 and GFAP are also observed in other neurological disorders, including stroke, multiple sclerosis, and traumatic brain injury, their measurement should be integrated into a broader panel of biomarkers, in order to avoid misinterpretation. The gene discussed is GFAP; the disease is Stroke.